Pravastatin reduces fibrinogen receptor gpIIIa on platelet‐derived microparticles in patients with type 2 diabetes

*Laboratory for Experimental Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam; Department of InternalMedicine, Slotervaart Hospital, Amsterdam; Laboratory of Haematology and Clinical Chemistry, Onze Lieve Vrouwe Gasthuis, Amsterdam; and§Department of Internal Medicine and Cardiovascular Research Institute Maastricht, Academic Hospital and University of Maastricht, Maastricht,The NetherlandsTo cite this article: Sommeijer DW, Joop K, Leyte A, Reitsma PH, ten Cate H. Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derivedmicroparticles in patients with type 2 diabetes. J Thromb Haemost 2005; 3: 1168–71.See also Davi` G, Ferroni P. Microparticles in type 2 diabetes mellitus. This issue, pp 1166–7.

[1]  C. Esmon,et al.  Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. , 1989, The Journal of biological chemistry.

[2]  G. Davı̀,et al.  Inhibition of throm☐ane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia , 1994 .

[3]  S. Nomura,et al.  Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. , 1995, Atherosclerosis.

[4]  D. Erkelens,et al.  Insulin resistance syndrome and type 2 diabetes mellitus. , 2001, The American journal of cardiology.

[5]  E. Dajani,et al.  Statins, platelet aggregation and coronary heart disease. , 2002, Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians.

[6]  Richard Barnett,et al.  Diabetes mellitus. , 1993, The Medical journal of Australia.

[7]  A. Goodall,et al.  Evaluation of Whole Blood Flow Cytometric Detection of Platelet Bound Fibrinogen on Normal Subjects and Patients with Activated Platelets , 1993, Thrombosis and Haemostasis.

[8]  J. Frohlich,et al.  Dyslipidaemia and coagulation defects of insulin resistance. , 2000, International journal of clinical practice. Supplement.

[9]  P. Reitsma,et al.  Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. , 2004, Diabetes care.

[10]  A. Simon,et al.  Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolemia. Effects of pravastatin. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[11]  R. Nieuwland,et al.  Elevated Numbers of Tissue-Factor Exposing Microparticles Correlate With Components of the Metabolic Syndrome in Uncomplicated Type 2 Diabetes Mellitus , 2002, Circulation.

[12]  A. Michael,et al.  Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. , 2003, British journal of clinical pharmacology.

[13]  B. Davis,et al.  Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.

[14]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[15]  D. Nie,et al.  Inhibition of platelet aggregation and expression of alpha granule membrane protein 140 and thromboxane B2 with pravastatin therapy for hypercholesterolemia. , 2002, Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians.

[16]  K. Maquelin,et al.  Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. , 1997, Circulation.

[17]  H. Parving,et al.  Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. , 2002, Diabetes.

[18]  A. Palazzuoli,et al.  Time‐dependent effect of statins on platelet function in hypercholesterolaemia , 2002, European journal of clinical investigation.

[19]  R. Westendorp,et al.  Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. , 2000, Blood.

[20]  R. Nieuwland,et al.  Microparticles in cardiovascular diseases. , 2003, Cardiovascular research.

[21]  V. Petrov,et al.  Influence of cholesterol-lowering on plasma membrane lipids and function. , 1996, Methods and findings in experimental and clinical pharmacology.